Neurotech embarks on ground-breaking ASD trials
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
This much-anticipated study is being conducted under the guidance and supervision of A/Professor Michael Fahey, Head of Paediatric Neurology Monash Children’s Hospital.
It will be the first time full-spectrum <0.3% THC medicinal cannabis strains will be assessed in ASD, and NTI/DOLCE lead strain (FEN 164) will assess key behaviours in ASD over 16 weeks including a 4-week washout period (no treatment).
Neurotech’s progress in this area hasn’t gone unnoticed over the last 12 months with the company’s shares up 700% over that period.
However, a slight retracement in April may just have thrown up a useful entry point for investors looking to take advantage share price catalysts that could emerge as a result of the study.
On this note, investors can expect to receive updates throughout the course of the study, suggesting there could be near-term market sensitive news.
Platform for study established through in vitro findings
Importantly, Neurotech embarks on the study with valuable research already suggesting that the NTI/Dolce strains, with the newly discovered rarer cannabinoids CBDP and CBDB, have powerful, unique properties that extend beyond CBD alone.
For example, results that have been observed include reduced inflammation with the brain cells and increased cell health and viability.
The strains displayed more potency than using CBD isolate alone with outperformance ranging between 30% and 80%.
In terms of efficacy, the company has not observed negative effects on cell health.
Commenting on the rigorous nature of the upcoming study, Fahey said, “It is exciting to undertake a properly planned and executed study on a novel CBD product.
‘"Many other studies do not have the rigor to ensure that the results are translatable to evidence-based clinical treatments.”
Commencement of discussions with TGA
Neurotech has commenced discussions with the TGA and relevant regulatory agencies for the therapeutic expansion and registration of these novel full spectrum plants.
Studies have been designed to assess dose escalation, efficacy and a 4-week wash-out period.
All patients will be monitored and assessed by Fahey and his team which comprises senior autism/ behavioural clinical psychologists.
The company’s Mente device will also be assessed in combination with the NTI/Dolce medicinal cannabis strains.
Discussing the significance of the potential outcomes in terms of quality of life, Neurotech chairman Brian Leedman said, "This is a very exciting and novel approach to the treatment of ASD for which there is the need for safe, effective therapies with no side effects that can improve a patient’s quality of life.
"Medicinal cannabis has the potential to provide this treatment, but only NTI/DOLCE naturally derived strains offer full-spectrum CBDs with no THC, an important consideration when treating children”.
Further reading: NTI Begins Autism Clinical Trials for Unique Cannabis Strain
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.